Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet nejm Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension Cagrilintide Semaglutide Blend 5mg 5mg Heritage Labs USA CagriSema outperforms Ozempic in Phase III trial Amr El Refaey CMI Level 7 Strategic Management Certificate posted on the topic LinkedIn